Vasoconstrictor cannabinoid analogs

US7109245B2 · kind B2 · utility

Assignees

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US
• Organix, Inc. · US

Inventors

• George Kunos · Bethesda, US
• Raj K. Razdan · Belmont, US

Key dates

• Filing date: Aug 14, 2002
• Grant date: Sep 19, 2006
• Expiry date: Aug 14, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising:wherein dashed lines independently represent either a single or a double bond, R1 is a lower alkyl, R2 is a lower alkyl, R3 is a lower alkyl or halogen, R4 is a lower alkyl or hydrogen, R5 is a lower alkyl or hydrogen, R6 is a hydrogen, lower alkyl or halogen, and R7 is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.